Virios Therapeutics, Inc. (VIRI)

NASDAQ: VIRI · IEX Real-Time Price · USD
0.381
+0.014 (3.88%)
At close: Sep 30, 2022 4:00 PM
0.380
-0.001 (-0.16%)
After-hours: Sep 30, 2022 7:57 PM EDT
3.88%
Market Cap 6.97M
Revenue (ttm) n/a
Net Income (ttm) -16.25M
Shares Out 18.33M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 627,456
Open 0.365
Previous Close 0.366
Day's Range 0.341 - 0.381
52-Week Range 0.341 - 9.111
Beta n/a
Analysts Buy
Price Target 7.14 (+1,776.5%)
Earnings Date Aug 11, 2022

About VIRI

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly kno... [Read more...]

Industry Biotechnology
IPO Date Dec 17, 2020
Employees 5
Stock Exchange NASDAQ
Ticker Symbol VIRI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for VIRI stock is "Buy." The 12-month stock price forecast is 7.14, which is an increase of 1,776.48% from the latest price.

Price Target
$7.14
(1,776.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Virios Therapeutics, Inc. Announces Closing of Public Offering

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

1 week ago - Business Wire

Virios Therapeutics, Inc. Announces Pricing of Public Offering

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

1 week ago - Business Wire

Virios Therapeutics, Inc. Announces Proposed Public Offering

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

1 week ago - Business Wire

Why Is Virios Therapeutics (VIRI) Stock Down 71% Today?

Source: Shutterstock / PopTika Virios Therapeutics (NASDAQ: VIRI ) stock is falling hard on Monday after the company revealed results from its Phase 2b Study of IMC-1 in Fibromyalgia. IMC-1 is a treatme...

1 week ago - InvestorPlace

Virios shares fall after sharing new clinical data about its fibromyalgia treatment candidate

Shares of Virios Therapeutics Inc. VIRI, +13.02% tumbled 64.3% in premarket trading on Monday after the company said its experimental fibromyalgia treatment did not meet the primary endpoint in a Phase ...

1 week ago - Market Watch

Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

1 week ago - Business Wire

Virios Therapeutics' Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

1 month ago - Business Wire

Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

1 month ago - Business Wire

Virios Therapeutics, Inc. to Present at Investor Summit Group's Q3 Virtual Conference

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

1 month ago - Business Wire

Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans

Company's September Phase 2b trial results could be transformative for fibromyalgia patientsNew York, New York--(Newsfile Corp. - August 8, 2022) - PCG Digital -- Life may change for the better for the ...

1 month ago - Newsfile Corp

Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August ...

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

1 month ago - Business Wire

Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment

Armed with near-term catalyst, VIRI is poised for next growth stageNew York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Development-stage biotechnology company Virios Therapeutics (NASD...

2 months ago - Newsfile Corp

Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results

New York, New York--(Newsfile Corp. - July 19, 2022) - PCG Digital -- With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia ("FM"), Virios Therapeutics (NA...

2 months ago - Newsfile Corp

Virios Therapeutics' Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex T...

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

4 months ago - Business Wire

Virios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

4 months ago - Business Wire

Virios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, ...

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

4 months ago - Business Wire

Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b “FORTRESS” Clinical Trial for Fibromyalgia

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debi...

5 months ago - Business Wire

Virios Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases ...

6 months ago - Business Wire

Virios Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thu...

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases,...

6 months ago - Business Wire

Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases,...

6 months ago - Business Wire

Virios Therapeutics Announces Research Collaboration Exploring the Potential of Combination Antiviral Therapy for Tre...

ATLANTA--(BUSINESS WIRE)---- $VIRI #COVID--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, i...

7 months ago - Business Wire

Virios Therapeutics to Present at the Virtual H.C. Wainwright BioConnect Conference

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chro...

8 months ago - Business Wire

Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chro...

10 months ago - Business Wire

Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chro...

10 months ago - Business Wire

Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November...

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and ...

10 months ago - Business Wire